SWOG clinical trial number
S9720
Phase II Trial of Paclitaxel and Carboplatin with Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma
Closed
Phase
Accrual
100%
Published
Abbreviated Title
ENDOMETRIAL
Activated
02/15/1998
Closed
07/15/2000
Participants
Members, Surgeons, Pathologists
Research committees
Gynecologic Cancer
Treatment
Amifostine
Paclitaxel
Carboplatin
Eligibility Criteria Expand/Collapse
Hist. conf. epithelial endometrial ca; metastatic or recurrent; not amenable to surgery or radiotherapy; bidimensionally measurable disease; no prior cytotoxic chemotherapy except for <= 2 courses for radiosensitization during primary definitive therapy; no prior taxanes; <= 1 prior biologic regimen; no concomitant RT, chemo or hormonal therapy, or immunotherapy (RT to bony metasases for pain control is allowed); >= 4wks since prior radiotherapy ( <= 30% to BM).
Publication Information Expand/Collapse
2005
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group
2001
Paclitaxel (PCT) and carboplatin (C) with amifostine (A) in advanced or recurrent endometrial cancer: a Southwest Oncology Group trial (S9720).